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Abstract: The goal of this study was to examine the efﬁ  cacy of liver-targeted gene delivery 
by chitosan-DNA nanoparticles through retrograde intrabiliary infusion (RII). The transfection 
efﬁ  ciency of chitosan-DNA nanoparticles, as compared with PEI-DNA nanoparticles or naked 
DNA, was evaluated in Wistar rats by infusion into the common bile duct, portal vein, or tail vein. 
Chitosan-DNA nanoparticles administrated through the portal vein or tail vein did not produce 
detectable luciferase expression. In contrast, rats that received chitosan-DNA nanoparticles 
showed more than 500 times higher luciferase expression in the liver 3 days after RII; and 
transgene expression levels decreased gradually over 14 days. Luciferase expression in the 
kidney, lung, spleen, and heart was negligible compared with that in the liver. RII of chitosan-
DNA nanoparticles did not yield signiﬁ  cant toxicity and damage to the liver and biliary tree as 
evidenced by liver function analysis and histopathological examination. Luciferase expression 
by RII of PEI-DNA nanoparticles was 17-fold lower than that of chitosan-DNA nanoparticles 
on day 3, but it increased slightly over time. These results suggest that RII is a promising 
routine to achieve liver-targeted gene delivery by non-viral nanoparticles; and both gene carrier 
characteristics and mode of administration signiﬁ  cantly inﬂ  uence gene delivery efﬁ  ciency.
Keywords: nanoparticles, gene delivery, liver-targeted, chitosan, retrograde intrabiliary 
infusion
Introduction
The liver represents one of the most important targets for therapeutic gene delivery 
because of the ready access of the transgene product to systemic circulation, 
and its susceptibility to many metabolic genetic disorders, viral infection and 
malignancies(Kren et al 2002; Prieto et al 2003; Nguyen and Ferry 2004). A critical 
barrier to realizing the potential of liver-targeted gene transfer is the development of a 
safe and efﬁ  cient gene carrier in combination with a feasible and efﬁ  cient administration 
route. Intravenous injection of naked plasmid DNA has showed no gene expression in 
the liver where the highest uptake is observed (Mahato et al 1995). High level of gene 
expression has been achievable in mouse and rat only by rapid injection of naked DNA 
in a large volume (∼8% body weight) (Liu et al 1999; Zhang et al 1999; Murakami et al 
2001; Higuchi et al 2003). The concern is that such a procedure may cause signiﬁ  cant 
mechanical damage, altering the physiological condition of the liver. Reducing the 
injection rate and volume to a physiologically acceptable range has been shown to 
abolish gene expression by lysosomal hydrolysis of the delivered DNA (Lecocq et al 
2003). These factors highlight the need for a gene carrier that can efﬁ  ciently protect 
DNA from degradation, facilitate its transport to the liver, and enhance its uptake by 
liver parenchymal cells (Nguyen and Ferry 2004).
Several gene carriers/vectors have been studied for liver-targeted gene delivery, 
including viral and non-viral vectors. Viral vectors, particularly adenovirus International Journal of Nanomedicine 2006:1(4) 508
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(Cristiano et al 1993; Nathwani et al 2002) and lentivirus 
(Cheung et al 2002), have demonstrated a high level of 
transgene expression. Viral vectors infect a wide variety 
of cell types in vivo (Jooss and Chirmule 2003); therefore, 
liver-targeted gene delivery can be achieved only by localized 
injection through the hepatic artery or portal vein (Nathwani 
et al 2002) or by conjugating the vectors to a polymer with 
hepatocyte-speciﬁ  c ligand (Cristiano et al 1993). However, 
signiﬁ  cant concerns exist about clinical applications of viral 
vectors (Treco and Selden 1995; Cichon et al 1999) such 
as host immune response against the vectors (Jooss and 
Chirmule 2003), intrinsic toxicity of the viral proteins, and 
limited packaging size.
As an alternative, several non-viral carriers have been 
evaluated for liver-targeted gene delivery (Li and Huang 
1997; Niidome and Huang 2002; Wu et al 2002). Liposomes 
and cationic polymers are the two most widely studied non-
viral carriers. Ligand-conjugated lipoplexes (Kawakami et al 
2002) and polymer-DNA complexes (Rogers et al 2000) have 
been constructed to achieve active targeting and enhance 
hepatocyte uptake through receptor-mediated endocytosis 
(Wu et al 2002). A signiﬁ  cant problem of these lipoplexes 
and polyplexes for liver-targeted gene delivery is that 
these complexes aggregate in serum following intravenous 
injection. These aggregates then become trapped in lung 
vasculature (Li and Huang 1997) and are scavenged by 
macrophages. Even when injected through a more direct 
route, eg, intraportal injection, these complexes mediated 
higher gene expression in the lung than in the liver (Li and 
Huang 1997; Otsuka et al 2000; Zhang et al 2001).
Retrograde intrabiliary infusion (RII) has recently been 
explored as a liver-targeted gene delivery route (Uehara et al 
1999; Otsuka et al 2000; Zhang et al 2001, 2003; Tominaga 
et al 2004). RII provides a direct delivery to parenchymal 
hepatocytes and avoids ﬁ  rst contact with Kupffer cells (KCs). 
The large surface area and broadly distributed biliary system 
provides great access to nearly all the hepatocytes in liver 
parenchyma (Ludwig et al 1998). Because of these obvious 
advantages, delivery of gene vectors (adenovirus, retrovirus, 
lipoplexes, and polyplexes) to the liver through RII has been 
investigated in rats ( Yang et al 1993; Terao et al 1998; De 
Godoy et al 1999; Uehara et al 1999; Kuhel et al 2000; 
Otsuka et al 2000; Tominaga et al 2004; Zhang et al 1997, 
2001 2003; Chen et al 2005), mice (Zhang et al 1997), pigs 
(Yang et al 1993; Otsuka et al 2000), and primates (Sullivan 
et al 1997). For example, Zhang et al (2001) showed that 
poly-L-lysine-molossin-DNA complexes (molossin is a 
polypeptide containing a 15-amino-acid integrin-binding 
domain), when directly infused to the portal vein of the rat 
liver, mediated a low level of transgene expressions, even 
with chloroquine-facilitated endolysosomal release of the 
complexes (Zhang et al 2003) On the other hand, the same 
complexes yielded about a 10-fold higher transgene expres-
sion when administered through RII. This was correlated 
with the prolonged presence of DNA in the liver after RII 
compared with intraportal infusion, where DNA was lost 
rapidly from the liver. Otsuka et al (2000) found that RII of 
multilamellar liposomes encapsulating DNA (0.3 mL/min) 
produced a 100-fold higher transgene expression than that 
given by intraportal vein infusion, which persisted for at 
least 6 days. These results suggest that RII is a promising 
administration route for liver-targeted gene delivery using 
non-viral vectors.
We have previously developed a nanoparticle gene 
delivery system based on a natural polymer, chitosan. 
Chitosan is a biodegradable and biocompatible polysaccharide 
derived from crustacean shells. Chitosan possesses several 
favorable characteristics for drug and gene delivery. Chitosan 
is soluble in acid solutions (pH<5.5) and can form complexes 
with anionic macromolecules to yield nanoparticles, 
microparticles, hydrogels, foams, and ﬁ  bers (Borchard 2001; 
Liu and Yao 2002). In particular, we have prepared chitosan-
DNA nanoparticles ranging from 150 to 300 nm in size. In 
addition, most of the positive charges in the chitosan polymer 
chain would be neutralized at physiological pH (pKa of the 
sidechain amino groups is 6.5), rendering chitosan molecule 
hydrophobic and less water soluble. This unique property 
ensures that chitosan-DNA nanoparticles formed at low pH 
remain stable at the physiological pH without chemical cross-
linking. Its mucoadhesive property and ability to enhance 
transepithelial transport of macromolecules across tight 
junctions make chitosan a natural carrier for mucosal delivery 
(Schipper et al 1997; van der Merwe et al 2004; Prego et al 
2005). We have shown in an oral DNA vaccine model that 
oral feeding of chitosan-DNA nanoparticles containing 
pCMVArah2 DNA encoding a major peanut allergen Arah2, 
elicited signiﬁ  cant levels of secretory IgA and Th1 type T 
cell response (serum IgG2a) against Arah2 at week 4, while 
oral immunization with naked DNA failed (Roy et al 1999). 
This Arah2-speciﬁ  c immune response could protect the 
animals from challenge (anaphylactic). Besides the peanut 
allergy model, we have also demonstrated the efﬁ  ciency of 
chitosan-DNA nanoparticles in an oral gene vaccine for dust 
mite allergen encoding Der p1 gene (Chew et al 2003) and 
in delivering Factor VIII gene orally (Bowman et al 2004). 
Successful transgene delivery has also been reported for International Journal of Nanomedicine 2006:1(4) 509
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intranasal and pulmonary administrations of chitosan-DNA 
nanoparticles (Koping-Hoggard et al 2001; Okamoto et al 
2003; Zhang et al 2005).
This study examined the potential of liver-targeted 
gene delivery mediated by intrabiliary infusion of polymer-
DNA nanoparticles. The gene delivery efﬁ  ciency, as well 
as the toxicity and damage to the liver and biliary tree, of 
chitosan-DNA nanoparticles administered through RII, 
intraportal infusion or tail vein injection were characterized 
in comparison with PEI-DNA complexes and naked DNA.
Materials and methods
Reagents
Polyethylenimine (branched PEI, average molecular weight of 
25 kDa), was purchased from Sigma-Aldrich (St Louis, MO, 
USA). PEI was puriﬁ  ed by dialysis against water (dialysis 
tubing with MWCO 3500; Pierce, Rockford, IL, USA) for 
3 days and lyophilization. Chitosan C390 (MW 390 kDa, 
deacetylation degree 83.5%) was kindly provided by Vanson 
Halosource (Redmond, WA, USA). Chitosan solution 
was prepared in 5 mM sodium acetate (NaAc) buffer at a 
concentration of 0.02 % (w/v). The pH of chitosan solution 
was adjusted to 5.5 and the solution was sterile-ﬁ  ltered 
through a 0.22 μm ﬁ  lter (Millipore, Billerica, MA, USA).
Ampliﬁ  cation of plasmid DNA
Plasmid pVR1255 is a 6,413b pcDNA encoding luciferase 
driven by human CMV promoter (a gift from Dr Carl J 
Wheeler, Vical Inc., San Diego, CA, USA). The plasmid was 
ampliﬁ  ed in Escherichia coli DH5α and puriﬁ  ed by Qiagen 
Giga plasmid puriﬁ  cation kit (endotoxin free, Qiagen, Hilden, 
Germany). Puriﬁ  ed plasmids were dissolved in saline and 
kept in aliquots at a concentration of 1 to 2 mg/mL. Terriﬁ  c 
Broth and ampicillin were purchased from Gibco BRL 
(Grand Island, NY, USA).
Preparation of chitosan-DNA 
and PEI-DNA nanoparticles
A chitosan solution (0.02% in 5 mM sodium acetate 
buffer, pH 5.5) and a DNA solution (100 μg/mL in 5 mM 
of NaAc solution) at an N/P ratio of 3 (N/P = molar ratio 
of chitosan nitrogen to DNA phosphate) were preheated 
to 50–55°C separately. An equal volume of both solutions 
were quickly mixed while vortexing. PEI-DNA nanoparticles 
were prepared by mixing PEI solution (133 μg/ml in 5% 
glucose) with equal volume of DNA solution (100 μg/ml in 
5% glucose) at an N/P ratio of 10. Both chitosan-DNA and 
PEI-DNA nanoparticles were incubated at room temperature 
for 30 min before characterization and transfection. The par-
ticle size and zeta potential of chitosan-DNA and PEI-DNA 
nanoparticles were measured on a Zetasizer® 3000 (Malvern 
Instruments, UK).
Bile degradation
Bile was isolated from rat common bile ducts over 30- to 
60-min periods and frozen at −80°C within a few hours. 
It was added to chitosan-DNA nanoparticles, PEI-DNA 
nanoparticles, and naked DNA solutions to reach the ﬁ  nal 
concentrations of 10% and 50% (v/v), respectively. The 
solutions were then incubated at 37°C. At different time 
points, aliquots of samples were taken, quenched at 4°C 
before analysis by electrophoresis on a 1% agarose gel and 
ethidium bromide staining for visualization.
To investigate the degradation mechanism of bile, an 
aliquot of rat bile sample was pretreated by heating in a 
boiling water bath for 15 min and cooled on ice. It was added 
to chitosan-DNA nanoparticles and naked DNA solutions 
at a ﬁ  nal concentration of 10%. In parallel, aliquots of 
chitosan-DNA nanoparticles and naked DNA were incubated 
with 10% untreated bile, 10% untreated bile with 50 mM 
of NAC, or 10 mM of hydrogen peroxide. The samples 
were incubated at 37°C. At 3-hour and 5-day time points, 
aliquots of samples were quenched at 4°C before analyzed 
by electrophoresis on a 1% agarose gel and ethidium bromide 
staining for visualization.
Animals
Six- to eight-week-old male Wistar rats were obtained and 
housed in National University of Singapore Animal Holding 
Unit. Rats were maintained on ad libitum rodent feed and water 
at room temperature, 40% humidity. All animal procedures 
were approved by the National University of Singapore 
Faculty of Medicine Animal Care and Use Committee.
Isolation and culture of hepatocytes, 
Kupffer cells, and normal rat 
cholangiocytes (NRC)
Hepatocytes were harvested from male Wistar rats weighting 
from 200 to 250 g by a two-step in situ collagenase perfu-
sion as described previously (Zhang et al 2001). Hepatocytes 
were collected by centrifugation twice at 50×g for 3 min. 
Hepatocytes (pellet) were seeded on collagen coated substrates, 
and maintained in William’s E medium supplemented with 
1 mg/mL BSA, 10 ng/mL of EGF, 0.5 μg/mL of insulin, 5 nM International Journal of Nanomedicine 2006:1(4) 510
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dexamethasone, 50 ng/mL linoleic acid, 100 U/mL penicillin, 
and 100 μg/mL streptomycin. The non-parenchymal cell 
fraction in the supernatant was washed with buffer and centri-
fuged at 650×g for 7 min at 4°C. Cell pellets were centrifuged 
on a density cushion of Percoll (25% and 50%) at 2500×g 
for 15 min at 4°C. The KCs fraction was then collected and 
seeded in a tissue culture ﬂ  ask, and cultured in RPMI 1640 
medium supplemented with 10% fetal bovine serum. Cell 
viability was determined using the Trypan Blue exclusion 
method. All cell culture media and supplements were from 
Gibco BRL (Grand Island, NY, USA) unless speciﬁ  ed. The 
NRC cell line was kindly provided by Dr Nicholas F LaRusso 
(Mayo Clinic, Rochester, MN, USA) and were maintained on 
collagen-coated tissue culture inserts with polyester membrane 
(6.5 mm, Nalge Nunc, Rochester, NY, USA) in DMEM/Ham’s 
F-12 medium with supplements as described by Vroman and 
LaRusso (Vroman and LaRusso 1996).
Transfection of primary rat 
hepatocytes, KCs, and NRCs
Isolated hepatocytes and KCs were seeded 24 hours prior 
to transfection into a 24-well plates at an initial density of 
3 × 105 cells per well. Before transfection, the medium in 
each well was replaced with 0.5 ml of fresh William’s E 
medium or RPMI 1640 for hepatocytes or KCs, respectively, 
with or without 10% bile. Nanoparticles containing 3 μg 
of DNA or 3 μg naked DNA was added to each well. The 
medium was refreshed after 4 h of incubation with cells. After 
48 hours, cells were lysed with cell lysis buffer (Promega). 
Transfection of NRCs was conducted in transwell inserts 
(Nalge Nunc) in a 24-well tissue culture plate. When the 
NRCs reached 70% conﬂ  uency, nanoparticles containing 
3 μg of DNA or 3 μg naked DNA was added to each well. 
The medium was refreshed after 4 hours of incubation with 
cells. The analysis of luciferase expression was conducted 
according to the same procedure described above.
Luciferase activity in the cell extract was measured on a 
luminometer (LUMAT LB9507, Berthold, Germany) using a 
luciferase assay system from Promega (Madison, WI, USA). 
The relative light units (RLU) are normalized against protein 
concentration in the cell extracts using a micro-BCA protein 
assay kit (Pierce, Rockford, IL, USA).
Luciferase expression following RII, 
intraportal, and intravenous injections 
of nanoparticles and plasmid DNA
Wistar rats (male, 200–250 g) were randomly assigned 
to groups of 15–17 rats. Animals were laparotomized 
under general anesthesia and the liver was isolated from 
the surrounding tissue. A 33G needle was inserted into 
the common bile duct and a tie was used to secure the 
needle. Nanoparticles and naked DNA were administered 
at the dose equivalent to 200 μg of plasmid (∼0.8 mg/kg 
of body weight) in 4 mL of medium into the common 
bile duct over 20 min (0.2 ml/min) using a syringe pump. 
A tie was then placed around the bile duct between the 
liver and the point of infusion to prevent back ﬂ  ow, and 
the needle was withdrawn. After 30 min, all ties were 
removed. The needle hole in the bile duct might require 
stitches with 10-O nylon suture (Ethicon, Somerville, 
NJ, USA) to prevent bile leakage, whenever necessary. 
Rats were kept on normal diet. For portal vein injection 
using a syringe pump, surgical operation was performed 
as previously reported (Zhang et al 2001). Nanoparticles 
or naked DNA was infused at 0.2 mL/min using the same 
DNA concentration as described above. Tail vein injection 
was also performed using a syringe pump through a 30 G 
needle over 2 min.
On days 3, 7, and 14, 5 rats from each group were 
sacriﬁ  ced. Major organs (liver, heart, lung, spleen, and 
kidney) were harvested and stored at –80°C for analysis. 
Each liver was divided into 4 sections composed of median, 
left, right, and caudate lobes. Two mL of lysis buffer (0.1% 
Triton X-100, 2 mM EDTA, and 0.1 M Tris-HCl, pH 7.8) 
per g of tissue was used for each sample, and the tissue was 
homogenized and subjected to 2 freeze-thaw cycles. The 
homogenates were centrifuged at 14000 rpm for 10 min. 
Luciferase activity in the homogenate was measured for 
10 sec on a luminometer and converted to the mass of lucif-
erase expressed per gram of tissue using a standard curve 
generated in parallel on the same luminometer. Student’s 
t-test was used to compare the difference between selected 
groups. Differences were considered statistically signiﬁ  cant 
when p<0.05.
DNA distribution after RII
of nanoparticles and naked DNA
To characterize DNA distribution, animals were injected with 
DNA nanoparticles containing 200 μg of Cy5-labeled plasmid 
DNA (pGeneGrip, Gene Therapy Systems, Inc.) through RII. 
Four hours after injection, major organs including liver, heart, 
spleen, lung, and kidney were resected, embedded in OCT 
medium, and frozen in liquid nitrogen as described above. 
For immunoﬂ  uorescence staining, cryosections (~8 μm) on 
microslides were ﬁ  xed in cold acetone, and incubated with 
Hoechst 33258 to stain cell nuclei. Staining of endothelial cells International Journal of Nanomedicine 2006:1(4) 511
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was performed with a mouse anti-rat mAb against rat endothelial 
cell antigen (5 μg/mL, RECA-1, ab9774, Abcam, Cambridge, 
MA, USA) and a goat anti-mouse IgG2a HRP conjugate 
(1:100; Zymed, San Francisco, CA, USA), using a Tyramide 
Signal Ampliﬁ  cation Fluorescein System (NEN, PerkinElmer, 
Wellesley, MA, USA). For staining of KCs, slides were incu-
bated with mouse anti-rat macrophage F-6-J mAb [ab8173; 
Abcam; 10 μg/mL in I-Block (Tropix, Applied Biosystems, 
Foster City, CA, USA) and subsequently with a F(ab)2 goat 
anti-mouse IgG-FITC Ab (Abcam; 7 μg/mL in I-Block). 
Slides were mounted with Gel/Mounting medium (Abcam) and 
evaluated under a Nikon confocal microscope equipped with 
an imaging system (Nikon Singapore, Singapore).
Damage/toxicity to liver and biliary tree 
following RII
Blood samples were drawn on days 1, 2, 3, 7, and 14 from 
the tested rats. ALT, AST, ALP, and bilirubin levels in 
serum samples were analyzed using a multiparametric auto-
matic analyzer in the Clinical Chemistry Laboratory at the 
National University Hospital in Singapore. Histopathological 
examination was performed on liver tissues collected at same 
time points. For collection of tissue, rats were anesthetized, 
perfused with 4% paraformaldehyde (PFA) in PBS, and 
euthanized. Extracted tissue will be further ﬁ  xed in 4% PFA, 
and routinely processed for parafﬁ  n-section. Sections will be 
stained with hematoxylin-eosin.
Results
Characterization of PEI-DNA 
and chitosan-DNA nanoparticles
The chitosan-DNA nanoparticles were prepared by complex 
co-acervation between chitosan and DNA according to 
the procedure reported previously (Leong et al 1998; Mao 
et al 2001). Size and surface charges signiﬁ  cantly affected 
the transfection and toxicity of the nanoparticles. We had 
identiﬁ  ed that the optimal N/P ratios for PEI-DNA nanopar-
ticles and chitosan-DNA nanoparticles were 10 and 3, 
respectively, for gene expression in the liver via RII in a pilot 
experiment (data not shown). These N/P ratios are consistent 
with other reported in vitro and in vivo gene transfer studies 
(Leong et al 1998; MacLaughlin et al 1998; Roy et al 1999; 
Mao et al 2001; Chew et al 2003; Tang et al 2003; Wang 
et al 2004). The following experiments are based on the 
PEI-DNA and chitosan-DNA nanoparticles prepared with 
these N/P ratios. At these N/P ratios, PEI-DNA nanoparticles 
displayed a high surface charge (+32 to +40 mV), with an 
average particle size of 170 nm, whereas chitosan-DNA 
nanoparticles exhibited a lower surface charge (∼+15 mV) 
and larger size (237 nm).
The stability of nanoparticles in bile or serum contain-
ing medium is one of the important factors that inﬂ  uence 
the particle transport and transfection efﬁ  ciency. We 
observed that addition of 10% rat bile to the nanoparticles 
suspension induced signiﬁ  cant aggregation (Table 1). 
Particles grew to a couple of microns in diameter within 
15 min of incubation, yielded a suspension with a bimodal 
distribution. For example, light scattering plot of chitosan-
DNA nanoparticles showed the majority (85–90% by 
number) of the particles in the range of 800–1200 nm and 
the remaining subset in the range of 2.5–3 μm. Particle 
size continued to grew until reaching a steady size after 
about 45 min of incubation. This aggregation behavior 
was likely due to the surface adsorption of negatively 
charged protein and bile salts present in the bile, leading 
to aggregation of positively charged nanoparticles. This is 
supported by the observation that zeta potential of DNA 
Table 1 Size and surface charge of chitosan-DNA and PEI-DNA nanoparticles in preparation solutions and 10% bile-containing buffer
Nanoparticles Particle size (nm) Zeta potential (mV)
in solutiona in 10% bileb in solutiona in 10% bileb
PEI-DNA 
(N/P=10)
170 ± 13 3986 ± 117 + (36 ± 4) – (24.5 ± 2.5)
Chitosan-DNA 
(N/P=3)
237 ± 32 3603 ± 155 + (15 ± 3) – (19 ± 4)
Notes: Size and zeta potential measurements were carried out 30 min after preparation, with or without bile incubation. Data represents average ± standard deviation of 
3 measurements.
aThe solution was 5% sucrose for PEI-DNA nanoparticles, and 50 mM sodium acetate buffer (pH 5.5) for chitosan-DNA nanoparticles.
bBile isolated from rat was added to the above mentioned solution to reach 10% ﬁ  nal concentration (v/v). Size and zeta potential were measured after 60 min incubation 
with 10% bile.
Abbreviation: PEI, polyethylenimine.International Journal of Nanomedicine 2006:1(4) 512
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particles changed to highly negative following contact 
with 10% bile – the average zeta potentials of PEI-DNA 
and chitosan-DNA particles were –24 mV and –19 mV, 
respectively. Aggregation of particles was also observed 
when PEI-DNA and chitosan-DNA nanoparticles were 
incubated with serum containing medium (10%–50%), 
but at a slower rate compared with that in bile containing 
buffer (data not shown).
Protection of plasmid DNA from bile 
degradation
Previously we have shown that chitosan-DNA nanoparticles 
render partial protection against nuclease degradation 
(Ludwig et al 1998). In order to characterize the potential 
protective effect during intrabiliary infusion, we incubated 
chitosan-DNA nanoparticles, PEI-DNA nanoparticles, or 
naked DNA with bile containing medium (10% and 50% 
bile in PBS, v/v) at 37°C, and examined the relative degrees 
of DNA degradation by gel electrophoresis. Degradation of 
naked DNA was apparent after incubating with 10% bile 
for 1 to 2 hours (Figure 1). Chitosan-DNA nanoparticles 
and PEI-DNA nanoparticles provided different degrees of 
protection to the encapsulated DNA. For chitosan-DNA 
nanoparticles, signiﬁ  cant DNA degradation was observed 
after 6–12 hours incubation in the presence of 10% bile. The 
protective effect decreased as bile concentration increased, 
and degradation of plasmid was observed after incubating 
with 50% bile for only 1–2 hours. On the other hand, only 
slight plasmid degradation was apparent from PEI-DNA 
nanoparticles after 12 hours incubation under the same 
conditions. These data suggested that both nanoparticle for-
mulations should render a signiﬁ  cant level of protection to 
plasmid against bile degradation. The difference observed 
between chitosan and PEI carriers could be attributed to the 
degradation of chitosan in bile-containing medium.
To determine whether bile-induced DNA damage is 
mediated by oxidative or enzymatic mechanisms, plasmid 
DNA was co-incubated for 3 hours at 37°C with 10% bile, 
10% bile that was preheated at 100°C for 15 min, and 
10% bile containing 50 mM of the anti-oxidant N-acetyl 
cysteine (NAC). As shown in Figure 2, the presence of 
NAC considerably preserved the super-coiled fraction 
of the plasmid, apparently preventing degradation and 
strand-breakage-induced linearization and nick-induced 
open coil formation in comparison to untreated and boiled 
bile incubations. Hydrogen peroxide (10 mM) treatment also 
mimicked the pattern of DNA fragmentation produced by 
bile treatment, whereas the DNA fragmentation was reduced 
Incubation
time (h)
Naked
pcDNA
Chitosan-DNA
Nanoparticles
Nanoparticles
PEI-DNA
Medium containing 10% bile Medium containing 50% bile
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Figure 1 Chitosan-DNA nanoparticles and PEI-DNA nanoparticles afford different 
degrees of protection to plasmid DNA in media containing 10% and 50% bile. To 
characterize the protection effect by nanoparticles in the presence of bile, chitosan-
DNA nanoparticles, PEI-DNA nanoparticles and naked DNA were incubated with 
10% or 50% bile diluted in PBS at 37°C. The relative degree of DNA degradation was 
analyzed by gel electrophoresis (0.8% agarose) and stained by ethidium bromide.
Abbreviation: PEI, polyethylenimine.
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Figure 2 Bile-induced DNA damage is primarily mediated by oxidative cleavage. 
Plasmid DNA and chitosan-DNA nanoparticles were incubated with (A) 10% bile, (B) 
10% preheated bile, (C) 10% bile with 50 mM of NAC, or (D) 10 mm H2O2 solution 
at 37°C for 3 hours and 5 days. The relative DNA degradation was analyzed by gel 
electrophoresis (0.8% agarose) and stained by ethidium bromide for visualization.
Abbreviation: NAC, N-acetyl cysteine.International Journal of Nanomedicine 2006:1(4) 513
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in the group treated with boiled bile and absent with bile 
treatment in the presence of NAC. These data suggest that 
oxidative DNA damage accounted for the majority of strand 
scission observed; and it was signiﬁ  cantly reduced by NAC 
treatment. Interestingly, neither DNA fragments nor intact/
nicked plasmid was observed when chitosan-DNA particles 
were treated with bile in the presence of NAC, indicating 
that chitosan was not degraded under this condition in order 
to release DNA or its fragments. Compared with data on 
nanoparticles treated with bile and boiled bile, these results 
indicated that degradation of chitosan is partially dependent 
on the oxidative condition in the bile (Yoo et al 2005). It is 
worth noting that the exposure of plasmid to bile during RII 
is probably much less than the conditions tested in terms of 
bile concentration and exposure time, because of the large 
volume infused.
Transfection of primary rat 
hepatocytes, KCs, and normal rat 
cholangiocytes (NRCs)
Previous reports have shown that the transfection efﬁ  ciency 
of chitosan-DNA nanoparticles was generally lower than 
that of PEI-DNA nanoparticles, and it is cell type-dependent 
(Ludwig et al 1998). Figure 3a shows the difference in 
transfection efﬁ  ciency of the two carriers in primary rat 
hepatocytes, KCs, and NRCs. Chitosan-DNA nanoparticles 
mediated a luciferase expression that was 4 orders of 
magnitude higher than background level; and transfections 
by chitosan-DNA nanoparticles were about 20 and 35 times 
less efﬁ  cient in NRCs and KCs, respectively. PEI-DNA 
nanoparticles were more efﬁ  cient, resulting in 26, 43, and 
25 times higher luciferase expression than chitosan-DNA 
nanoparticles in transfecting hepatocytes, NRCs, and KCs, 
respectively. Interestingly, naked DNA alone effected more 
than 500 and 260 times higher luciferase activities than back-
ground level in hepatocytes and KCs, whereas it remained 
inefﬁ  cient in NRCs.
We also investigated whether the exposure to bile 
would affect the transfection efﬁ  ciency of nanoparticles. 
The transfection was carried out by exposing hepatocytes 
with nanoparticles or naked DNA in the absence or presence 
of 10% bile added in the medium. Bile containing 
medium was replaced with fresh medium after 4 hours 
of incubation with cells. The presence of bile almost 
completely abolished transgene expression mediated by 
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Figure 3 Transfection efﬁ  ciency of PEI-DNA and chitosan-DNA nanoparticles and naked DNA in primary rat hepatocytes, Kupffer cells (KCs) and normal rat cholangiocytes 
(NRCs).   (a).   Transfection efﬁ  ciency in three types of cells. Hepatocytes and KCs were transfected in 24-well dishes with the indicated complexes containing 3 μg VR1255 
pcDNA for 4 hours. Luciferase expression was analyzed 48 hours after transfection. Relative light units were normalized to protein content and are the mean ± standard 
deviation of 2 independent experiments (n = 4). (b). Comparison of transfection efﬁ  ciency in primary rat hepatocytes in the presence and absence of bile (10%). Cells were 
transfected in a medium containing 10% bile for 4 hours, and normal medium for 44 hours before luciferase analysis (n = 4).
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PEI-DNA nanoparticles and naked DNA (Figure 3b). 
Chitosan-DNA nanoparticles retained a low level of 
transfection activity. This high sensitivity of nanoparticles 
and naked DNA to bile underscores the importance of 
developing strategies to stabilize the nanoparticles. The 
reduction of transfection efficiency by nanoparticles in 
bile containing medium could be due to a combination of 
nanoparticle aggregation and degradation of particles and 
DNA. In addition, gene expression in hepatocytes might also 
be dampened by the cytotoxicity of bile, which is evident from 
relative cell numbers at the end of transfection experiment 
(data not shown).
Luciferase expression in rat liver 
and other organs following RII, 
intraportal, and tail vein infusions 
of nanoparticles and naked DNA
Transfection efﬁ  ciency was analyzed using luciferase as a 
reporter gene. Nanoparticles were prepared using VR1255 
plasmid. When given by tail vein infusion, chitosan-DNA 
nanoparticles, PEI-DNA nanoparticles and naked DNA 
groups all showed background level of luciferase expression 
on days 3, 7, and 14 (Figure 4). When given by intraportal 
vein infusion, PEI-DNA nanoparticle was the only group 
showing positive transgene expression (~3 times higher 
than background level, p<0.05) during the first week. 
Chitosan-DNA nanoparticles and naked DNA both failed to 
show any detectable level of luciferase expression.
RII, on the other hand, was a much more efﬁ  cient delivery 
route. Three days after RII, rats that received chitosan-DNA 
nanoparticles showed a luciferase expression of 33 pg/g of 
tissue; this level is over 500 times greater than background 
signal in the luciferase expression assay observed in PBS 
controls (p<0.01). Gene expression level decreased over 
time to 0.6 pg/g of tissue on day 14. PEI-DNA nanoparticles 
were slightly less efﬁ  cient than chitosan-DNA nanoparticles. 
Luciferase expression was about 17-fold lower than that 
by chitosan-DNA nanoparticles on day 3, but it increased 
by about 2 fold on day 7 and was maintained at the similar 
level for at least 2 weeks. Surprisingly, naked DNA given 
by RII also gave a transient luciferase expression (0.62 pg/g 
of tissue) on day 3 (p<0.05).
Lobular structure of the rat liver provided a convenient 
system to analyze the distribution of transgene product in the 
liver following RII. The distribution of transgene product 
in the liver was slightly different between chitosan-DNA 
and PEI-DNA nanoparticles (Figure 5). In chitosan-DNA 
nanoparticle-transfected rats, luciferase expression in the 
left lobe was consistently 3 to 4 times lower than other lobes 
of the liver (p<0.05) at the early time points. This might 
be a result of the nanoparticle aggregation in bile duct and 
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Figure 4 Luciferase expression in rat liver following RII, intraportal infusion and tail vein injection of chitosan-DNA nanoparticles, PEI-DNA nanoparticles, and naked DNA. 
Each bar represents mean ± standard deviation (n = 5). Chitosan C390 and VR1255 plasmid were used in this experiment. Chitosan-DNA and PEI-DNA nanoparticles were 
prepared at N/P ratios of 3 and 10, respectively. Nanoparticles and naked DNA were infused to rats at a dose equivalent to 200 μg of plasmid per rat (∼0.8 mg/kg of body 
weight) in 4 mL of medium into the common bile duct (0.1 ml/min) or portal vein (1 ml/min), or tail vein (1 mL/min). On days 3, 7, and 14, 5 rats from each group were sac-
riﬁ  ced, and livers were harvested and homogenized in lysis buffer and analyzed for luciferase activity. Rats receiving 4 mL of PBS infusions were included as the background 
control that deﬁ  nes the detection limit for this assay at 0.04 pg luciferase/g tissue.
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canaliculi that limited the transport through the canaliculi to 
the left lobe of the liver. This difference was not signiﬁ  cant 
on day 14. The expression levels among different lobes 
of the liver transfected with PEI-DNA nanoparticles were 
similar on day 3. Nevertheless, the right and caudate lobes, 
which are closer to the infusion point, seemed to have higher 
expression at later time points.
Transgene distribution among different organs was 
different for gene transfers mediated by chitosan-DNA 
nanoparticles and PEI-DNA-nanoparticles (Figure 6). 
This information is important not only in evaluating the 
liver-targeting effect by the carriers, but also in understanding 
particle transport mechanism. In rats receiving intrabiliary 
infusion of chitosan-DNA nanoparticles, transgene expression 
levels in the kidney, lung, spleen, and heart were negligible 
(p<0.01). However, in PEI-DNA nanoparticle-transfected 
rats, low level of luciferase expressions were detected in the 
lung, spleen, and heart, even though the expression in the 
liver still accounted for more than 95% of the total transgene 
expression.
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Figure 5 Luciferase expression in different lobes of the rat liver following intrabiliary injection of chitosan-DNA nanoparticles or PEI-DNA nanoparticles containing 200 μg 
of DNA. Each bar represents mean ± standard deviation (n=5). Experimental condition were the same as described in Figure 3.
Abbreviation: PEI, polyethylenimine.
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Figure 6 Luciferase expression in major organs of the rats after receiving intrabiliary injection of chitosan-DNA nanoparticles or PEI-DNA nanoparticles containing 200 μg 
of DNA. Each bar represents mean ± standard deviation (n=5). Experimental conditions are the same as described in Figure 3.
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Distribution of DNA following RII 
of nanoparticles and naked DNA
To characterize the distribution of nanoparticles and naked 
DNA following RII, plasmid DNA was labeled with Cy5 
using pGeneGrip technology before nanoparticle preparation. 
Tissues from major organs were harvested 4 hours after 
infusion, and cryo-sectioned for the examination of 
Cy5-labelled plasmid. For animals that received nanopar-
ticles, the reporter gene was detected throughout the liver, 
although the pattern was rather heterogeneous; occasionally 
clusters of Cy5 ﬂ  uorescence were found in close proximity 
to vessel structure or portal triads (Figures 7a, b). Only a low 
level of reporter gene was found in naked DNA-transfected 
rats, highlighting the importance of gene carriers. Comparing 
the two nanoparticle groups, more ﬂ  uorescence was observed 
for the PEI-DNA nanoparticle group than the chitosan-DNA 
nanoparticle group. The relative levels of reporter gene 
observed in the tissue, however, seemed to contradict the 
relative levels of transgene expression in the liver: chitosan-
DNA nanoparticles showed a lower level of presence in the 
liver, but yielded higher level of luciferase expression, in 
contrast to PEI-DNA nanoparticles. This may be due to the 
fact that chitosan is degradable, therefore resulting in higher 
level of DNA release following cell uptake.
Another possibility is that more PEI-DNA nanoparticles 
were taken up by KCs than chitosan-DNA nanoparticles. 
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Figure 7 Confocal ﬂ  uorescence images indicating DNA distribution in the right lobe of the liver that received naked DNA and nanoparticles via RII. Liver samples were 
collected 4 hours after intrabiliary infusion of chitosan-DNA or PEI-DNA nanoparticles containing 200 μg of Cy5 labeled DNA (pGeneGrip) or 200 μg of naked Cy5-DNA. 
(a–c): distribution of DNA (red); (d–h): co-localization of DNA (red) and KCs (green). KCs were stained with FITC-labeled mouse anti-rat macrophage F-6-J mAb. (i–k): 
co-localization of DNA (red) and endothelial cells (ECs, green). Endothelial cells were identiﬁ  ed by immunostaining with FITC-labeled mouse anti-rat RECA-1 mAb.
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This is supported by additional immunoﬂ  uorescence staining 
for KCs using an antibody speciﬁ  c for rat macrophages 
(Figures 6d–h). Even though the majority of cells that 
took up reporter gene (or particles) were hepatocytes, we 
observed a signiﬁ  cantly higher level of DNA co-localization 
with KCs in the PEI-group (Figures 6e, g), compared with 
chitosan-group and naked DNA group. It is also interesting 
to note that there was a substantially higher number of 
KCs observed in the PEI-groups than the other two groups. 
Relatively lower frequency of KCs found in the chitosan-
group might be related to the anti-inﬂ  ammatory effect of 
chitosan (Chou et al 2003; Seo et al 2003; Kim et al 2004). 
We have observed a very low degree of co-localization 
between reporter gene and endothelial cells (Figures 6i–k), 
indicating a lower level of uptake of nanoparticles by 
endothelial cells. On the other hand, we did observe the 
passage of PEI-DNA particles through the endothelium 
occasionally (arrow in Figure 7j).
Despite the fact that low levels of gene expression 
were observed in heart, spleen, lung, and kidney in rats 
receiving PEI-DNA nanoparticles, we failed to observe 
Cy5-ﬂ  uorescence (reporter gene) in these organs. This is 
likely due to low sensitivity of this assay method.
Toxicity/damage to the liver and biliary 
tree by RII of nanoparticles 
and naked DNA
The acute liver damage and toxicity following RII of 
nanoparticles and naked DNA were assessed by analyzing 
serum aspartate transaminase (AST) and alanine transaminase 
(ALT) levels during the experimental period, in comparison 
with the infusions of PEI-DNA nanoparticles (Figure 8). 
A slight increase in serum AST and ALT activities was observed 
1 day after the administration of naked DNA, followed by a 
rapid decrease to the normal level by day 3. Chitosan-DNA 
nanoparticles mediated only a moderate increase of both 
ALT and AST activities, slightly higher than that of naked 
DNA group. In contrast, signiﬁ  cant elevation of both AST 
and ALT in the PEI-DNA nanoparticle group was observed 
(∼1150 IU/L for ALT and ∼900 IU/L for AST). The levels 
of alkaline phosphatases (ALP) were monitored to reﬂ  ect 
potential damage to biliary tree. The ALP levels followed 
the same trends for all three groups (Figure 8). The transient 
increase of ALP level indicated that mild damage to biliary tree 
occurred in response to the infusion pressure, but this damage 
was transient. Nanoparticle infusions caused higher levels of 
ALP during the ﬁ  rst two days. Throughout the experimental 
period, bilirubin levels for all groups were in the normal range 
(5–30 IU/L), indicating that there was no obstructive jaundice 
caused by the injection procedure (data not shown).
Histopathological examination conﬁ  rmed these conclu-
sions. Figure 9 showed tissue reactions in the liver 3 days 
after nanoparticle and naked DNA infusions. Liver sections 
from a naked DNA-infused rat showed minimal changes 
with patchy mild bile ductular proliferation and mild reactive 
changes in the biliary epithelium (Figure 9c). The reactive 
bile ducts/ductules appeared regenerative with increased 
mitoses, decreased basophilic cytoplasm, and increased 
nuclear size with open chromatin. Most of portal tracks 
are essentially normal (Figure 9d). The focal and limited 
proliferation of hepatocytes and ductular cells is in good 
agreement with the result by Polimeno et al (1995) showing 
that stimulation of a signiﬁ  cant proliferative response requires 
obstruction of the bile duct for longer than 24 hours. Rats 
that received chitosan-DNA nanoparticles showed some 
mild biliary changes with a higher level of diffused but mild 
bile ductular proliferation and biliary epithelial reactive/
regenerative changes (Figures 9e, f); other portal tracks were 
normal. PEI-DNA nanoparticles induced a stronger biliary 
tract change than chitosan-DNA nanoparticles. In addition to 
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bile ductular proliferation and reactive epithelial changes, 
some sections showed portal edema and signiﬁ  cant portal 
inﬂ  ammation (Figures 9g, h). No animals showed evidence 
for lobular hepatitis, vascular ﬂ  ow abnormalities, lobular 
cholestasis, or portal ﬁ  brosis. Long-term morphological dam-
ages to the liver and biliary tree remain to be characterized. 
Biochemical analyses discussed above suggest that these 
damages were transient.
Discussion
Retrograde intrabiliary infusion has several advantages that 
make it attractive for improving liver-targeted gene transfer 
efﬁ  ciency. The biliary system is distensible with a large bile 
duct volume (∼29 mL for human liver). It consists of 7–10 
orders of cholangiographically visible bile ducts spanning 
the expanse of the hepatic parenchyma (Saxena et al 2003). 
This large surface area (eg, the ultrastructural surface of 
an entire normal biliary tree for a human liver would be 
around 3000 cm2) and broadly distributed biliary system 
provides great access to large number of hepatocytes in liver 
parenchyma through bile canaliculi (Ludwig et al 1998). RII 
achieves a more direct delivery to parenchymal hepatocytes 
than intraportal vein infusion and tail vein injection; and 
avoids ﬁ  rst contact with serum and KCs lining endothelium, 
even though leakage through tight junction to Space of 
Disse and hepatic sinusoid likely occurs under this infusion 
condition. RII of adenovirus (Ad5) encoding LacZ gene 
yielded transfection of similar expression levels (∼30%) and 
Figure 9 Histopathological examination of liver tissue extracted on day 3 from rats received naked DNA (c and d), chitosan-DNA nanoparticles (e and f), or PEI-DNA 
nanoparticles (g and h), in comparison with the naïve rat (a and b). Liver samples were collected on day 14, cryosectioned (8 μm thickness), and stained with H&E.
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duration in hepatocytes as that delivered through intraportal 
infusion, however, re-administration of Ad by RII on day 35 
and 70 induced similar level of re-expression of transgene 
in the liver, despite the fact that the ﬁ  rst administration of 
Ad5 also generated neutralizing antibody in the serum. This 
was in contrast to that by intraportal infusion, which failed 
to show gene expression upon re-administration (Tominaga 
et al 2004). No cholangiocytes were stained positive. The 
distinct outcome of these two delivery routes highlights the 
advantage of RII as a more efﬁ  cient route for liver-targeted 
gene delivery.
One particular concern for RII delivery of plasmid DNA 
is the degradation and damage to DNA by contact with 
bile. Bile has long been known to cause DNA damage and 
strand breakage, having been implicated as a mutagen in 
colon cancer (Cheah and Bernstein 1990) and biliary tract 
carcinoma (Masamune et al 1997). In particular, strand 
breakage has been shown to occur through the production 
of hydroxyl radicals and other reactive oxygen species by 
the bilirubin-Cu(II) complex (Asad et al 1999, 2002). The 
decreased fragmentation in the presence of boiled bile 
indicates that a native protein, such as bilirubin, might be 
involved, although signiﬁ  cant nuclease activity is effectively 
precluded by the marked protective effect of NAC treatment 
(Figure 2). NAC is commonly administered as an antioxidant 
to treat paracetamol poisoning of the liver. It could thus be 
readily added to the solution after nanoparticle formation 
or used as a pre-treatment prior to nanoparticle delivery to 
further enhance the delivery efﬁ  ciency.
Compared with literature-reported RII procedures 
(Otsuka et al 2000; Zhang et al 2001, 2003), we made two 
modiﬁ  cations in our procedure: (1) the infusion was carried 
out with a syringe pump in order to achieve a consistent ﬂ  ow 
and reproducible results. Understandably, this minimizes 
the potential hepatic and biliary damage as the intrabiliary 
pressure can be maintained steady during infusion; (2) the 
intrabiliary infusion was given through the common bile duct 
to the whole liver, as opposed to infusion only to one of the 
liver lobes (Otsuka et al 2000; Zhang et al 2001, 2003) This 
is apparently a more practical procedure to be adapted in 
the clinical setting.
In the literature, infusion rate ranging from 0.02 to 
2.7 mL/min have been tested for RII in various experiments 
in rats, including non-transfection related studies (Coleman 
et al 1989; De Godoy et al 1999; Zhang et al 2001; Chen 
et al 2005). Although no systematic study has been reported 
on examining the effect of infusion rate and volume on 
transfection efﬁ  ciency, it is assumed that there is a balanced 
condition that correlates with high transfection and acceptable 
hepatic injury and toxicity (De Godoy et al 1999; Zhang et al 
2001; Chen et al 2005). It has been shown that rats do not 
tolerate high infusion rate (0.4–2.25 mL/min) and high infu-
sion volume (>4 mL) well (Coleman et al 1989; Chen et al 
2005). A pilot study suggested that using our protocol, an 
infusion rate up to 0.25 min/mL and a total infusion volume 
of 2–4 mL could be well tolerated by Wistar rats. For the 
purpose of comparing the delivery efﬁ  ciency of different gene 
carriers, we ﬁ  xed the infusion rate at 0.2 mL/min and infusion 
volume at 4 mL for intrabiliary infusion in this study.
Our study demonstrated that the transgene expression is 
both administration route-dependent and carrier dependent. 
Among the three administration routes tested, RII showed 
the highest transgene expression in the liver for all both 
nanoparticle groups and naked DNA. Even naked DNA 
delivered by RII yielded about 10-times higher transient gene 
expression than background level; whereas intraportal and 
tail vein infusion both failed to show any expression. Gene 
expressions by PEI-DNA and chitosan-DNA nanoparticles 
showed very different kinetics. Chitosan was 17 times more 
efﬁ  cient than PEI under the test condition, but the expression 
was more transient than PEI. PEI-DNA nanoparticles 
showed a more persistent level of gene expression, even 
though the maximum level of gene expression was 6-fold 
lower than that of chitosan-DNA nanoparticles. These 
data suggested that polymeric carrier improves transgene 
expression delivered through RII, but the level and kinetics 
of transgene expression is dependent on the nature of gene 
carrier. In addition, the difference in transgene expres-
sion between the two types of carriers in vivo (Figures 4 
and 6) does not correlate with that in vitro (Figure 3). These 
differences could be related to the degradation of chitosan 
in vivo, even though chitosan degradation is not appreciable 
in typical cell culture medium. Macrophages present in the 
liver (Kupffer cells) and other tissues may also play a role in 
modulating chitosan degradation and nanoparticle clearance, 
therefore inﬂ  uence the transgene expression in vivo (Chellat 
et al 2005).
Both nanoparticles mediated less transgene expression 
in the left lobe, a distance lobe from the infusion point, 
suggesting that particle aggregation could be barrier to 
achieving uniform transfection throughout the liver. This is 
also corroborated by the observation that both nanoparticles 
aggregate upon contact with 10% bile or medium. Further 
improvement of the colloidal stability of the nanoparticles 
will likely increase the transfection efﬁ  ciency and the acces-
sibility of nanoparticles to the whole liver tissue.International Journal of Nanomedicine 2006:1(4) 520
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Immunoﬂ  uorescence microscopy also suggested that 
DNA uptake was restricted to focal areas; and DNA 
was associated with hepatocytes and to a lesser extent 
with macrophages. It is also of importance to investigate 
whether biliary epithelial cells (cholangiocytes) can 
be transfected under this RII condition. No signiﬁ  cant 
level of DNA was found in the portal triad region in the 
ﬂ  uorescence microscopy study; neither did we observe 
β-galactosidase expression in the portal triad region in a 
transfection experiment using LacZ as the reporter gene 
(data not shown). This is consistent with literature reports 
showing very limited transfection in cholangiocytes with 
liposomes (Otsuka et al 2000), PLL-DNA complexes 
(Zhang et al 2001, 2003), and adenovirus (Tominaga 
et al 2004) using RII protocols. Detailed localization of 
gene expression with cholangiocytes is currently under 
investigation.
Of particular note is the different pattern of distribution 
in transgene expression among major organs mediated by 
chitosan-DNA nanoparticles and PEI-DNA nanoparticles 
following RII. No signiﬁ  cant gene expression was detected 
in organs other than the liver in the chitosan group, in contrast 
to signiﬁ  cant luciferase expression observed in lung, spleen 
and heart for PEI-DNA nanoparticles on days 3 to 14. Positive 
gene expression in other organs suggested that transport of 
nanoparticles from the bile canaliculi to hepatic sinusoid 
and hepatic vein occurred, and a higher degree of “leakage” 
occurred for PEI-DNA nanoparticles, compared with chitosan-
DNA nanoparticles. Nevertheless, it is also possible that 
chitosan-DNA nanoparticles were transported to other organs 
at a similar degree but failed to transfect those tissues. Consid-
ering the acute disruption of the tight junctions under mildly 
elevated pressure, RII actually can be viewed as an alternative 
route to deliver genes to hepatic sinusoid, although detailed 
transport mechanism remains to be characterized.
Our RII protocol mounted a mild level of hepatic toxicity/
damage as evidenced by the transient and slight elevation 
of the AST, ALT, and ALP levels following naked DNA 
delivery. Understandably, the degree of liver and biliary 
tree damage should be dependent on the infusion rate and 
volume (Roy et al 1999; Mao et al 2001; Chew et al 2003). 
Chitosan and PEI increased the AST, ALT, and ALP levels 
signiﬁ  cantly at early time points, but PEI showed much 
higher toxicity/damage than chitosan (ALT and AST levels in 
PEI group were 3 times higher than that of chitosan group on 
the ﬁ  rst day). This suggests that gene carrier does contribute 
to and is probably the most signiﬁ  cant factor in the acute 
toxicity/damage by this route of delivery.
Efforts in optimizing non-viral vector-mediated gene 
transfer have been centered on the design and modiﬁ  cation 
of gene vectors and constructs. More studies are needed 
to systematically optimize the non-viral gene vector 
properties in concert with the administration route. This 
study demonstrates that the optimal characteristics of a gene 
carrier are closely dependent upon the administration route; 
and establishes the feasibility of RII for liver-targeted gene 
delivery using biodegradable and biocompatible nanopar-
ticles. It is important to note that in clinical settings RII can 
be achieved via endoscopic retrograde cholangiopancrea-
tography (ERCP), a routine bile duct canulation procedure 
(Chia et al 2000). This study laid the foundation for further 
optimization of nanoparticles to enhance liver-targeted 
gene delivery and for systematic study on the mechanism 
of nanoparticle transport to liver parenchymal cells through 
different routes.
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